Hyrimoz

Approved Uses

Hyrimoz is used to reduce the signs and symptoms of various autoimmune and inflammatory diseases. It is approved for use in adults and, in some cases, children.

Joint Conditions

• Rheumatoid Arthritis: To treat moderate to severe symptoms and help prevent further joint damage.
• Psoriatic Arthritis: To reduce pain and swelling and improve physical function.
• Ankylosing Spondylitis: To treat inflammation of the spine and joints.
• Juvenile Idiopathic Arthritis: To treat moderate to severe polyarticular JIA in children 2 years of age and older.

Skin and Eye Conditions

• Plaque Psoriasis: For adults with moderate to severe chronic plaque psoriasis who may benefit from systemic therapy or phototherapy.
• Hidradenitis Suppurativa: To treat moderate to severe cases of this chronic skin condition.
• Uveitis: To treat certain types of non-infectious inflammation in the eye.

Digestive Conditions

• Crohn's Disease: To treat moderate to severe symptoms in adults and children 6 years of age and older.
• Ulcerative Colitis: To treat moderate to severe symptoms in adults when other medicines have not worked well enough.

Mechanism of Action

Hyrimoz belongs to a class of medications known as tumor necrosis factor (TNF) blockers. TNF is a protein naturally produced by the body's immune system. In people with certain autoimmune conditions, the body produces too much TNF, which leads to persistent inflammation, pain, and swelling.

Hyrimoz works by:

• Binding to TNF: The medication attaches itself to TNF-alpha proteins in the bloodstream and tissues.
• Blocking signals: By binding to these proteins, Hyrimoz prevents them from reaching and activating the receptors on healthy cells that trigger inflammation.
• Reducing immune response: This action helps to calm an overactive immune system, which can slow or stop the progression of damage to joints, skin, or the digestive tract.

Because Hyrimoz targets a specific part of the immune system, it is considered a biologic medication. It helps manage symptoms and can prevent further physical damage caused by chronic inflammatory diseases.

Common Side Effects

The most frequently reported side effects of Hyrimoz include:

• Injection site reactions, such as pain, redness, itching, or swelling.
• Upper respiratory infections or sinus infections.
• Headache.
• Rash.
• Nausea.

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Signs of infection: Fever, chills, persistent cough, muscle aches, or feeling very tired.
• Allergic reactions: Hives, swelling of the face, lips, or tongue, and difficulty breathing.
• Nervous system problems: Numbness or tingling, dizziness, vision changes, or weakness in the legs.
• Liver problems: Yellowing of the skin or eyes (jaundice), dark urine, or pain on the right side of the stomach area.
• Heart failure: New or worsening shortness of breath, swelling of the ankles or feet, or sudden weight gain.
• Blood disorders: Fever that does not go away, bruising or bleeding easily, or looking very pale.
• Immune reactions: Joint pain or a rash on the cheeks or arms that gets worse in the sun (lupus-like syndrome).

Serious Infections

Hyrimoz can lower the ability of the immune system to fight infections. Some people have developed serious infections while taking this medication, including tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. These infections may require hospitalization and can be fatal. Testing for TB is necessary before starting treatment and should continue during therapy. Treatment is typically withheld if a serious infection develops.

Cancer Risks

There is an increased risk of certain types of cancer, including lymphoma and skin cancer. A rare and fatal type of cancer called hepatosplenic T-cell lymphoma has occurred in some people, primarily teenagers and young adult males with inflammatory bowel disease who were also using other specific medications. Regular skin examinations are often recommended to check for non-melanoma skin cancers.

Neurological and Blood Disorders

This medication may increase the risk of new or worsening nervous system problems, such as multiple sclerosis or Guillain-Barré syndrome. It can also cause serious blood problems, where the body does not make enough blood cells to fight infections or stop bleeding. Symptoms such as persistent fever, bruising, or paleness should be reported immediately.

Other Precautions

• Hepatitis B Reactivation: The hepatitis B virus can become active again in people who carry it in their blood. This can lead to severe liver damage or death.
• Heart Failure: New or worsening heart failure has been reported in people taking TNF blockers like Hyrimoz.
• Allergic Reactions: Serious allergic reactions, including anaphylaxis, can occur. These require immediate medical attention.
• Vaccinations: Live vaccines should be avoided while using this medication, as the immune system may not respond appropriately.
• Lupus-like Syndrome: Some people may develop symptoms similar to lupus, such as a rash or joint pain, which usually improve after stopping the drug.

Pregnancy

There is limited information regarding the safety of using Hyrimoz during pregnancy. Research indicates that adalimumab products cross the placenta, particularly during the third trimester. This means the medication can reach the developing fetus.

While some data does not show a significant increase in the risk of major birth defects, the evidence is not yet sufficient to determine a definitive risk level. Healthcare providers typically recommend using this medication during pregnancy only if it is clearly necessary.

Infant Health Considerations

If you use Hyrimoz during pregnancy, your baby may have a higher risk of infection after birth. It is important to inform your child's pediatrician about your use of this medication. Live vaccines should generally be avoided in infants exposed to Hyrimoz in the womb for at least five to six months after the mother's last dose.

Breastfeeding

Hyrimoz is known to pass into breast milk in small amounts. However, it is thought that the medication is not well-absorbed by the infant's digestive system. You should discuss the benefits of breastfeeding and the potential risks to your infant with your doctor to determine the best course of action for your situation.

Available Forms

Hyrimoz is supplied as a sterile, preservative-free solution for injection under the skin. It is available in the following formats:

• Prefilled Pen: A single-dose device designed for subcutaneous administration.
• Prefilled Syringe: A single-dose glass syringe with a fixed needle.

These delivery systems are intended for single use only and should be discarded after the dose is administered.

FDA Approval and Indications

Hyrimoz (adalimumab-adaz) is a biological medication approved by the U.S. Food and Drug Administration (FDA) as a biosimilar to Humira. It is approved for use in adults and some pediatric patients to treat conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

Boxed Warning

The FDA has issued a boxed warning for Hyrimoz, which is the most serious type of warning for prescription medications. The warning includes:

• Serious Infections: Patients are at an increased risk for developing serious infections that may lead to hospitalization or death. These include tuberculosis (TB), bacterial sepsis, and invasive fungal infections. Healthcare providers must test patients for latent TB before starting treatment and monitor them for signs of infection during therapy.
• Malignancy: Cases of lymphoma and other cancers, some fatal, have been reported in children and adolescent patients treated with TNF blockers like Hyrimoz.

Regulatory Status

Hyrimoz is available only by prescription. It is required to be dispensed with a Medication Guide that provides important safety information to patients. In 2024, the FDA approved a high-concentration, citrate-free formulation of Hyrimoz as an interchangeable biosimilar. This designation allows the medication to be substituted for the reference product (Humira) at the pharmacy level without a new prescription from the healthcare provider, depending on individual state laws.

Factors Influencing Cost

The amount a patient pays for Hyrimoz can vary significantly based on several factors:

• Insurance Coverage: Most commercial insurance plans and Medicare Part D cover Hyrimoz, but the specific copayment or coinsurance depends on the plan's formulary tier.
• Pharmacy Choice: Because Hyrimoz is a biologic medication, it is typically dispensed through specialty pharmacies, which may have different pricing structures than standard retail pharmacies.
• Prior Authorization: Many insurance providers require prior authorization, meaning the healthcare provider must justify the medical necessity of the drug before coverage is approved.

Biosimilar Status and Pricing

Hyrimoz is a biosimilar to the reference product Humira (adalimumab). Biosimilars are FDA-approved medications that are highly similar to an original biologic drug in terms of safety and effectiveness. They are often introduced to the market to increase competition and potentially lower the overall cost of treatment for inflammatory conditions.

Financial Assistance and Support

Patients may be able to reduce their out-of-pocket expenses through various support options:

• Copay Savings Cards: The manufacturer may offer savings cards for patients with commercial insurance that can significantly lower monthly copays.
• Patient Assistance Programs: For individuals who are uninsured or underinsured, programs may be available to provide the medication at a reduced cost or for free, depending on financial eligibility.
• Step Therapy: Some insurance plans may require patients to try other, often less expensive, medications before they will cover the cost of Hyrimoz.

Patients are encouraged to contact their insurance provider and the manufacturer's support services to understand the specific costs and assistance options available to them.